Tech Company Financing Transactions
Akari Therapeutics Funding Round
Akari Therapeutics closed a funding round on 9/22/2015. Investors included Deerfield Capital and private investors.
Transaction Overview
Company Name
Announced On
9/22/2015
Transaction Type
Venture Equity
Amount
Unknown
Round
Undisclosed
Investors
Deerfield Capital (Lead Investor) (Jean Kim)
Proceeds Purpose
Akari plans to use the anticipated net proceeds from the private placement for the clinical development of Coversin.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
75-76 Wimpole St.
London, W1G 9RT
UK
London, W1G 9RT
UK
Phone
Email Address
Not Recorded
Overview
Akari is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Clive Richardson
Browse more venture capital transactions:
Prev: 9/22/2015: 20/20 GeneSystems venture capital transaction
Next: 9/22/2015: CoverHound venture capital transaction
Share this article
About Database of VC Transactions
We do our best to record funding rounds that are announced publicly. All VC database entries reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs